Genomic medicine market is projected to reach USD 123 billion by 2035; AI in genomics USD 6.5 billion; viral vector manufacturing USD 15.83 billion. Gene therapy trials drive growth.
Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
Three biotech companies announce significant funding: Korsana Biosciences secures $175 million for neurodegenerative therapies, Kos Biotechnology Partners closes a $123 million life sciences fund, and ParcelBio launches with $13 million to advance mRNA medicines.
Multiple market reports forecast the global biologics and antibody therapy markets will reach hundreds of billions of dollars by the 2030s, driven by monoclonal antibodies, biosimilar expansion, and targeted therapies.
CARsgen Therapeutics has signed a RMB370 million agreement to build a CAR T-cell manufacturing base in Shanghai, supporting commercialization of its marketed and late-stage products. Meanwhile, investment firm HarbourVest disclosed a $21 million position in CAR-T developer Generate Biomedicines, which holds $516.6 million in cash after its IPO.
The FDA granted Breakthrough Device Designation to TOBY Inc.'s urine-based Alzheimer's diagnostic test and Instanosis Inc.'s Xylazine Rapid Test (Urine), accelerating development of both non-invasive diagnostic technologies.
CRISPR Therapeutics said CASGEVY launch momentum is building and multiple pipeline assets could generate data in the next 12 to 18 months. The company also highlighted zugo-cel progress in oncology and autoimmune disease.
Sino Biopharmaceutical won Chinese approval for a new indication for benmelstobart as maintenance therapy in unresectable stage III NSCLC after chemoradiotherapy. Phase III R-ALPS data showed significantly prolonged progression-free survival versus placebo and a manageable safety profile.
The FDA said one pivotal trial plus confirmatory evidence will become the default standard for approval of most new drugs. The shift could extend beyond rare diseases to common conditions affecting millions.
Ray Therapeutics received EMA PRIME designation for its RTx-015 optogenetic gene therapy for retinitis pigmentosa, following recent FDA RMAT status. The company also appointed Michael Murtagh as Chief Regulatory Officer to support global development.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07754565 |
Fatıgue Management and Qualıty of Lıfe |
COMPLETED | NA |
| NCT07680556 |
Promoting Response to IMmunotherapy by Exercise in Patients With Advanced Renal Cell Carcinoma |
RECRUITING | NA |
| NCT07652502 |
Physical Exercise During the Cancer Care Pathway |
NOT_YET_RECRUITING | |
| NCT07635901 |
Exercise Intervention for Chemotherapy-Induced Peripheral Neuropathy |
COMPLETED | NA |
| NCT07633236 |
Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy |
RECRUITING | PHASE3 |
| NCT07615218 |
Enhancing Cancer Care: Patient Navigation Through EORTC Quality-of-Life Insights at Sohag Oncology Center |
COMPLETED | |
| NCT07593053 |
Phase I Prognostic Online (PIPO) Tool |
COMPLETED | |
| NCT07592234 |
Chemokeyp: A Feasibility Study for Realtime Safety Data-Capture for Potential Serious Adverse Drug Events |
RECRUITING | |
| NCT07532083 |
Implementing AI-Assisted, Patient-Friendly Imaging Report Summaries to Enhance Oncology Care Delivery |
RECRUITING | |
| NCT07504263 |
Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
